Astrazeneca (AZN) Shares Outstanding (Weighted Average) (2009 - 2026)

Astrazeneca's Shares Outstanding (Weighted Average) history runs 18 years deep, the most recent figure standing at $388.0 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) changed 0.0% year-over-year to $388.0 million; the TTM figure through Mar 2026 stood at $388.0 million (changed 0.0% YoY), while the FY2025 annual figure was $388.0 million, changed 0.0% from the prior year.
• Shares Outstanding (Weighted Average) was $388.0 million for Q1 2026 at Astrazeneca, roughly flat from $388.0 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $1.5 billion in Q2 2022 to a low of $250000.0 in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $456.0 million across 5 years, with a median of $388.0 million in 2023.
• Biggest YoY gain for Shares Outstanding (Weighted Average) was 154700.0% in 2023; the steepest drop was 99.94% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $387.0 million in 2022, then advanced by 0.26% to $388.0 million in 2023, then changed by 0.0% to $388.0 million in 2024, then changed by 0.0% to $388.0 million in 2025, then changed by 0.0% to $388.0 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $388.0 million (Q1 2026), $388.0 million (Q4 2025), and $388.0 million (Q3 2025), per Business Quant data.